Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-week dose-ranging study of oral QBW251 in COPD patients on triple inhaled therapy
jRCT2080224866Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2019
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of Icenticaftor in chronic obstructive pulmonary disease (COPD) (6 arms), sponsored by Novartis. Primary endpoint: Trough FEV1 at Week 12. Started Sep 2019; status: completed.
02
Drugs
Icenticaftor
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on jRCT2080224866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224866.